GH
Guardant Health, Inc.
A precision-oncology company that spots cancer with simple blood tests, including the Shield test, the first FDA-approved blood test for colorectal cancer screening, plus the Guardant360 CDx for guiding treatment and Guardant Reveal for watching for recurrence. Co-founded in 2012 by two Stanford PhDs, Helmy Eltoukhy and AmirAli Talasaz, it was built on the idea of catching cancer's genetic "signature" floating in the bloodstream. Its Shield test was designed to make cancer screening as easy as a routine blood draw, avoiding the preparation many people dread.
CUSIP: 40131M109HealthcareUS4 holders
Total Value
$124.96M
Total Shares
1.04M
Net Share Change
-161.2K
Activity
1 buying3 selling
Investor
Value
Shares
Weight
Change
